Indoco Remedies Limited — Updates, 10-03-2025: Press Release

Indoco Remedies Limited's Clinical Research Organisation, AnaCipher, has successfully completed a comprehensive US FDA inspection. Conducted from March 3 to March 7, 2025, the inspection assessed both clinical and bioanalytical phases of three Bioavailability and Bioequivalence studies. While a Form 483 was issued at the conclusion of the inspection, Indoco plans to address the observations within the specified timeframe. This marks a significant milestone for the company, underscoring its commitment to regulatory compliance and quality standards. Indoco's strong global presence is supported by a turnover of approximately USD 212 million and a workforce of over 6,000 employees, including 400 skilled scientists. The achievement enhances AnaCipher's credibility and positions Indoco for potential growth in the pharmaceutical sector.